In the clinical research landscape, researchers can use many different types of trials to test a new drug or treatment. Each has its own benefits and drawbacks, which are heavily assessed and considered before a trial type is decided. One type of clinical trial is a non-inferiority trial.
While most standard clinical trials seek to show that a new treatment is better than an existing one, non-inferiority trials aim to show that the new treatment is not unacceptably worse than the existing one. In other words, it may be slightly less effective, but by no more than a small, pre-agreed amount, and it usually offers another advantage, such as fewer side effects or easier use.
Looking to participate in a clinical trial? Don't know where to start?
Our clinical trial platform can connect you with trials that match your needs and eligibility. Take the first step towards accessing cutting-edge treatments and start your search today to discover the potential benefits of participating in clinical trials.
The purpose of non-inferiority trials
In non-inferiority trials, researchers aim to demonstrate that the test treatment is not worse than a comparator by more than a predefined amount. The predefined amount is typically known as the non-inferiority margin, or delta, while the comparator is usually an already established and active treatment.
This type of clinical trial is commonly used when an effective treatment already exists, so it would not be ethical to give participants a placebo instead. Non-inferiority trials have an important role in the clinical research landscape, supporting researchers in developing and evaluating new medical treatments. With the data collected, clinical researchers can provide valuable information for clinicians and patients when making treatment decisions.
What is the non-inferiority principle?
The non-inferiority principle refers to the concept used in this type of clinical trial to determine whether a new treatment is as effective as one already in existence. The burden of proof is on the new treatment: the trial must show convincingly that it is not worse than the established one by more than the pre-set margin.
Researchers use this principle to compare two treatments without requiring one to be significantly better than the alternative. Instead, it allows clinicians to focus on ensuring the new treatment is not significantly worse than the existing one.
What treatments are tested in non-inferiority trials?
Many different treatments are tested in non-inferiority trials, including new medicines that offer advantages such as fewer side effects, a simpler schedule, or a lower cost. Generics and biosimilars are usually assessed differently, through bioequivalence studies or comparative studies designed to show that they are equivalent to the original medicine. Reformulated drugs, including extended-release versions of existing medications, can also be tested to confirm they are not less effective while potentially improving patient adherence.
Non-inferiority trials can also assess dosage forms and administration methods. For example, researchers may test oral medications versus injectables or topical treatments versus systemic treatments. Researchers will compare these methods to establish whether they have similar efficacy with potentially better patient compliance or fewer side effects.
New surgical methods or medical devices could also be evaluated to confirm they are not inferior to traditional methods. Clinicians will seek to determine outcomes of different types, to see if benefits like less invasiveness or quicker recovery times could be established.
Another common focus in non-inferiority trials is vaccines, with new vaccines tested to ensure they provide comparable immune responses to active ones. Fewer side effects or broader protection could be key areas of consideration for researchers testing vaccines with this type of trial.
Finally, non-inferiority trials can be used for new therapeutic regimens. For example, shorter treatment durations or different dosing schedules could be tested to determine whether they are as effective as standard regimens, while offering greater convenience or cost-efficiency.
Key features of a non-inferiority trial
Non-inferiority trials have several key features that set them apart from other types of clinical trials.
- Objective: The primary objective of a non-inferiority trial is to show that the new treatment's effectiveness is not significantly worse than the standard or existing treatment.
- Non-inferiority margin: The non-inferiority margin is a pre-specified threshold set out by researchers at the beginning of the trial. It defines the maximum allowable difference in efficacy between the new treatment and the existing one. The margin needs to be small enough to make sure the new treatment's efficacy is clinically acceptable.
- Control group: Most clinical trial types have a control group, as is the case in non-inferiority trials. The control group in these trials receives the standard treatment to provide a benchmark for comparison.
- Statistical considerations: In non-inferiority trials, the analysis is concerned with whether the new treatment's efficacy falls within the non-inferiority margin. Typically, researchers use confidence intervals to determine if the outcome difference is within the acceptable range.
- Sample size: Non-inferiority trials often need large numbers of participants, because showing that two treatments differ by less than a narrow margin requires precise estimates. The narrower the margin, the more participants are needed.
The benefits and challenges of non-inferiority trials
Like all types of clinical trials, non-inferiority trials have several advantages and disadvantages. Each of these should be carefully considered before a research team decides to use this method as part of their clinical research.
The advantages of non-inferiority trials
Non-inferiority trials offer a number of advantages over traditional trial methodologies. Firstly, they allow researchers to test new treatments when withholding effective treatment would be unethical, because every participant receives an active treatment. They can show that a treatment with other advantages, such as fewer side effects or a simpler schedule, works well enough to be a real alternative.
Another advantage is that a positive result can make treatment cheaper, simpler, or more convenient for patients, for example a shorter course of treatment or a pill instead of an injection, even if the trial itself is large.
Non-inferiority trials also have the potential to provide evidence for several treatment options, offering more choices for patients and healthcare professionals. This can be beneficial both in terms of treatment outcomes and cost.
Finally, non-inferiority trials are able to uncover valuable information about the safety and tolerability of a new treatment. This is vital for patient wellbeing and ensuring patients are receiving the best care and most relevant treatment for their condition.
The limitations of non-inferiority trials
Like any clinical trial type, non-inferiority trials can also pose challenges and limitations. While they offer valuable information about the effectiveness of a new treatment, researchers will need to consider the limitations of the methodology before proceeding.
A key limitation of non-inferiority trials is the choice of non-inferiority margin. This predetermined threshold establishes how much worse the new treatment can be compared to the comparable existing treatment. However, the margin is often subjective and can have a large impact on the interpretation of the trial results.
Another challenge is trial quality. In a superiority trial, problems such as participants missing doses or dropping out tend to hide real differences and make it harder to show a benefit. In a non-inferiority trial, the same problems make two treatments look more alike, which can make it easier to conclude non-inferiority wrongly. Careful conduct and analysis are therefore especially important. Non-inferiority trials also rely on the assumption that the comparison treatment is working as well in the trial as it did in earlier studies.
Like other clinical trials, non-inferiority trials can also be subject to potential bias, lack of blinding, and difficulty in recruiting and retaining participants.
The difference between non-inferiority trials and other trials
We’ve already mentioned that non-inferiority trials have many differences when compared to other types of clinical trials. Understanding these differences is crucial for researchers to make informed decisions on the type of trial they should use. The differences between trials can also help clinical research teams establish clear evaluations on whether a new treatment is effective enough to be used in place of an existing one.
Placebo-controlled trials vs non-inferiority trials
The key difference between placebo-controlled trials and non-inferiority trials is the objective and control used in the trial.
Placebo-controlled trials have an objective to prove that a new treatment is effective when compared to no treatment. This makes them vital for determining the baseline efficacy of a new treatment. Non-inferiority trials, however, seek to show that a new treatment is comparably effective to an existing treatment while having the potential to offer other benefits.
Another difference in these trials is when they are used. Placebo-controlled trials are used at many stages of research, especially when there isn’t another standard treatment available or when the new treatment is added on top of standard care. Non-inferiority trials are commonly used when a proven treatment is already in existence and being used but researchers seek to establish whether the new treatment offers more advantages.
Both types of clinical trials are valuable and can be used effectively in clinical research. While placebo-controlled trials are critical for determining the efficacy of new treatments against no intervention, non-inferiority trials are important for testing new treatments that may offer more benefits over what’s already available.
Equivalence trials vs non-inferiority trials
Objectives and margins for comparison are the key differences between equivalence trials and non-inferiority trials.
Equivalence trials aim to show that two treatments have no meaningful differences in their efficacy, while non-inferiority trials only require researchers to show that the new treatment is not significantly worse than the standard treatment available. This means that equivalence trials need to show that the new treatment’s effect falls within a narrow range on both sides of the standard treatment’s effect. For non-inferiority trials, researchers only focus on one side of the margin.
Superiority trials vs non-inferiority trials
Once again, superiority trials and non-inferiority trials place their differences in their objectives and outcomes.
Superiority trials seek to prove that a new treatment is better than an existing one or a placebo. This is in contrast to non-inferiority trials which aim to establish that a new treatment is not unacceptably worse than the existing one. Superiority trials require a demonstration of a statistically significant improvement, while non-inferiority trials must show that any loss of effectiveness stays within a pre-defined, clinically acceptable margin.
The outcome of a superiority trial is to show that a new treatment is more effective in terms of efficacy, making them crucial in establishing clear clinical benefits. However, non-inferiority trials seek to demonstrate that a new treatment could be a viable alternative, potentially offering different benefits outside the efficacy factor.
Can you claim superiority in a non-inferiority trial?
As non-inferiority trials aim to demonstrate that a new treatment is simply not inferior to the standard treatment, superiority is not the key focus. However, once non-inferiority has been shown, researchers can go on to test whether the new treatment is actually better, as long as this step was planned in advance. The opposite does not work: a failed superiority trial cannot simply be reinterpreted as a non-inferiority result.
Non-inferiority trial examples
A shorter tuberculosis treatment. Standard treatment for tuberculosis lasts six months. In a large international trial published in 2021, a four-month regimen that included the antibiotics rifapentine and moxifloxacin was shown to be non-inferior to the standard six-month course. A shorter treatment is easier to complete, which matters a great deal for a disease that needs months of daily pills.
Pills instead of a drip. In a UK trial published in 2019, people with serious bone and joint infections who switched to antibiotic tablets early were compared with people who continued antibiotics through a drip. The tablets were shown to be non-inferior, meaning many patients could avoid weeks of intravenous treatment.
Vaccines. New vaccines, or new versions of existing ones, are often tested in non-inferiority trials that compare the immune response they produce with that of an approved vaccine, as in many vaccine clinical trials.
How to get involved in a non-inferiority clinical trial
If you’re interested in volunteering in a clinical trial, it’s possible to get involved in a non-inferiority trial in many different ways. The first step is to look for a clinical trial that is relevant to you and currently recruiting participants. You can do this by searching online databases or speaking with your healthcare professional.
If you have a specific illness or condition, you may also be able to speak to local groups about any clinical trials they are aware of. Many group organizers have access to this information and can pass on the recruitment details to you.
Once you’ve found a trial taking on participants, you should research the clinical trial and its purpose to ensure it is suitable for you. You can do online research or speak directly with the trial coordinator to ask any questions you may have about the trial.
The benefits of taking part in a non-inferiority trial
Taking part in a non-inferiority trial can be hugely beneficial for everyone, including participants, patients and the wider medical community. Because the comparison is an established treatment, everyone in a non-inferiority trial receives an active treatment rather than a placebo. The new treatment can still have unknown side effects, which the study team explains before you agree.
For patients, you could gain access to new therapies that could offer similar efficacy to what you’re already using, with potential added benefits such as fewer side effects, greater convenience, or lower costs. You may even find that the new treatment works better for you in terms of efficacy.
For healthcare professionals and researchers, non-inferiority trials are beneficial for introducing alternative treatments that could enhance patient care and provide solutions when standard treatments are either unsuitable or unavailable.
Conclusion
Non-inferiority trials are a crucial methodology in clinical research, enabling researchers to validate new treatments and determine whether there are additional benefits when compared to existing treatments, while keeping efficacy within an acceptable margin of the existing treatment. They enhance the patient care journey and ensure that patients are continually offered the best and most suitable care for their condition, while potentially delivering improved convenience, safety and cost-efficiency.
Common questions
What does non-inferiority mean in simple terms? That a new treatment is not unacceptably worse than an existing one. It may be slightly less effective, but only within a small margin agreed before the trial, and it usually brings another benefit.
What is a non-inferiority margin? The largest loss of effectiveness that researchers and regulators would accept in exchange for the new treatment’s other advantages. It is set before the trial starts.
Do non-inferiority trials use a placebo? Usually not. They compare the new treatment with an established, effective one, so every participant receives an active treatment. Our guide to placebo-controlled trials explains when placebos are used.
What is the difference between non-inferiority and equivalence? A non-inferiority trial only checks that the new treatment is not too much worse. An equivalence trial checks that it is neither too much worse nor too much better, so the two can be considered interchangeable.
Are non-inferiority trials randomized? Usually yes. Most are randomized controlled trials with an active control group.
